Cargando…

The role of phosphodiesterase-5 inhibitors in prostatic inflammation: a review

Clinical and basic experimental evidence indicates that chronic inflammation is the greatest factor in benign prostatic hyperplasia (BPH) progression, which is the most common cause of Lower Urinary Tract Symptoms (LUTS). The use of anti-inflammatory agents such as steroids, cyclooxygenase-2 (COX-2)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Peixoto, Christina Alves, Gomes, Fabiana Oliveira dos Santos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4570643/ https://www.ncbi.nlm.nih.gov/pubmed/26379476 http://dx.doi.org/10.1186/s12950-015-0099-7

Ejemplares similares

Phosphodiesterase-5 Inhibitors: Action on the Signaling Pathways of Neuroinflammation, Neurodegeneration, and Cognition
por: Peixoto, Christina Alves, et al.
Publicado: (2015)

Anti-infection mechanism of phosphodiesterase-5 inhibitors and their roles in coronavirus disease 2019 (Review)
por: Su, Hao, et al.
Publicado: (2021)

Erectile dysfunction and heart failure: the role of phosphodiesterase type 5 inhibitors
por: Al-Ameri, H, et al.
Publicado: (2009)

Phosphodiesterase-5 inhibitors and the heart: compound cardioprotection?
por: Hutchings, David Charles, et al.
Publicado: (2018)

A phosphodiesterase 5 inhibitor, tadalafil, suppresses stromal predominance and inflammation in a rat model of nonbacterial prostatitis
por: Sugimoto, Mikio, et al.
Publicado: (2019)

Peyronie's Disease: Evolving Surgical Management and the Role of Phosphodiesterase 5 Inhibitors
por: Al-Shaiji, Tariq F., et al.
Publicado: (2009)

Effects of phosphodiesterase type 5 inhibitors on choroid and ocular vasculature: a literature review
por: da Cruz, Natasha Ferreira Santos, et al.
Publicado: (2020)

The effect of phosphodiesterase-5 inhibitors on cerebral blood flow in humans: A systematic review
por: Pauls, Mathilde MH, et al.
Publicado: (2017)

Evolution of Phosphodiesterase-5 Inhibitors
por: Moon, Du Geon
Publicado: (2015)

Phosphodiesterase-5 Inhibitors as Therapeutics for Cardiovascular Diseases: A Brief Review
por: Corbic, Milena, et al.
Publicado: (2023)

The Wonders of Phosphodiesterase-5 Inhibitors: A Majestic History
por: Elhwuegi, AS
Publicado: (2016)

Role of phosphodiesterase 5 in synaptic plasticity and memory
por: Puzzo, Daniela, et al.
Publicado: (2008)

The first‐generation phosphodiesterase 5 inhibitors and their pharmacokinetic issue
por: Zucchi, A., et al.
Publicado: (2019)

COVID-19 and Phosphodiesterase Enzyme Type 5 Inhibitors
por: Al-Kuraishy, Hayder M., et al.
Publicado: (2020)

Phosphodiesterase Type 5 Inhibitors and Visual Side Effects: A Narrative Review
por: Barroso, Francisco, et al.
Publicado: (2021)

Advancements in Phosphodiesterase 5 Inhibitors: Unveiling Present and Future Perspectives
por: ElHady, Ahmed K., et al.
Publicado: (2023)

Repurposing phosphodiesterase-5 inhibitors as chemoadjuvants
por: Tiwari, Amit K., et al.
Publicado: (2013)

Upregulation of Phosphodiesterase type 5 in the Hyperplastic Prostate
por: Zhang, Wenhao, et al.
Publicado: (2015)

Selective Phosphodiesterase 4B Inhibitors: A Review
por: Azam, Mohammed Afzal, et al.
Publicado: (2014)

Phosphodiesterase type 5 inhibitors usage and prostate cancer: a match-paired analysis
por: Machen, G. Luke, et al.
Publicado: (2017)

Role of phosphodiesterase-4 inhibitors in chronic obstructive pulmonary disease
por: Rhee, Chin Kook, et al.
Publicado: (2020)

Phosphodiesterase type 5 inhibitors for treating erectile dysfunction and lower urinary tract symptoms secondary to benign prostatic hyperplasia: A comprehensive review
por: Haddad, Albert, et al.
Publicado: (2015)

Current Concepts on the Reno-Protective Effects of Phosphodiesterase 5 Inhibitors in Acute Kidney Injury: Systematic Search and Review
por: Georgiadis, Georgios, et al.
Publicado: (2020)

Phosphodiesterase type 5 inhibitors: back and forward from cardiac indications
por: Corinaldesi, C., et al.
Publicado: (2015)

Phosphodiesterase-5 inhibitors in management of pulmonary hypertension: safety, tolerability, and efficacy
por: Buckley, Mitchell S, et al.
Publicado: (2010)

Preference for and adherence to oral phosphodiesterase-5 inhibitors in the treatment of erectile dysfunction
por: Giannitsas, Konstantinos, et al.
Publicado: (2008)

New Avenues for Phosphodiesterase Inhibitors in Asthma
por: Matera, Maria Gabriella, et al.
Publicado: (2021)

Phosphodiesterase-5 inhibitors: Emerging nephroprotective drugs
por: Abassi, Zaid, et al.
Publicado: (2015)

Phosphodiesterase-5 inhibitors for colon cancer chemoprevention
por: Islam, Bianca N., et al.
Publicado: (2018)

Counterfeit phosphodiesterase type 5 inhibitors pose significant safety risks
por: Jackson, G, et al.
Publicado: (2010)

Chronic Low Dosing of Phosphodiesterase Type 5 Inhibitor for Erectile Dysfunction
por: Sung, Hyun Hwan, et al.
Publicado: (2012)

Could Oral Phosphodiesterase 5 Inhibitors Have a Potential Adjuvant Role in Combating COVID-19 Infection?
por: Mostafa, Taymour
Publicado: (2021)

Clinical and preclinical treatment of urologic diseases with phosphodiesterase isoenzymes 5 inhibitors: an update
por: Zhang, Wen-Hao, et al.
Publicado: (2016)

Systematic Review of the Effects of Phosphodiesterase-5 Inhibitors and Dexamethasone on High Altitude Pulmonary Edema (HAPE)
por: Bliss, Amy, et al.
Publicado: (2019)

AB030. Evolution of phosphodiesterase type 5 inhibitors
por: Moon, Du Geon
Publicado: (2016)

The Effect of Phosphodiesterase-type 5 Inhibitors on Erectile Function: An Overview of Systematic Reviews
por: Pyrgidis, Nikolaos, et al.
Publicado: (2021)

Phosphodiesterase Inhibitors as a Therapeutic Approach to Neuroprotection and Repair
por: Knott, Eric P., et al.
Publicado: (2017)

Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast
por: Gooderham, Melinda, et al.
Publicado: (2015)

Methylxanthines and Phosphodiesterase Inhibitors in the Treatment of Airways Disease
por: Semple, S J G
Publicado: (1995)

Role of Phosphodiesterase-5 Inhibitors in Acute Right Ventricular Failure Due to Pulmonary Embolism
por: Sharma, Munish, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_duvmkbfuocglfvk3hhlpenvict